<DOC>
	<DOCNO>NCT02208544</DOCNO>
	<brief_summary>The purpose study determine whether use molecular image use FDG-PET/CT could prevent unnecessary diagnostic thyroid surgery case indeterminate cytology fine-needle aspiration biopsy .</brief_summary>
	<brief_title>FDG-PET/CT Evaluation Cytological Indeterminate Thyroid Nodules Prevent Unnecessary Surgery ( EfFECTS )</brief_title>
	<detailed_description>Rationale : Only ¼ patient thyroid nodule indeterminate cytology proven suffer malignancy diagnostic hemithyroidectomy . Therefore ~¾ operate upon unbeneficially . Recent study use FDG-PET/CT suggest decrease fraction unbeneficial procedure ~73 % ~40 % . Thereby direct cost per patient , number hospitalization average sick leave day might decrease experienced HRQoL might increase . A study undertaken show additional value FDG-PET/CT indeterminate cytology respect unbeneficial procedure , cost utility . Main objective : To determine impact FDG-PET/CT decreasing fraction patient cytologically indeterminate thyroid nodule undergo unbeneficial patient management . Study design : A prospective , multicentre , randomize , stratify control blinded trial experimental study-arm ( FDG-PET/CT-driven ) control study-arm ( diagnostic hemithyroidectomy , independent FDG-PET/CT-result ) . Study population : Adult patient cytologically indeterminate thyroid nodule , without exclusion criterion , 15 ( university regional ) hospital distribute Netherlands . Intervention : One single FDG-PET/low-dose non-contrast enhance CT head neck perform patient . Patient management depend allocation result FDG-PET/CT . Main study parameters/endpoints : The number unbeneficial intervention , i.e . surgery benign disease watchful-waiting malignancy . Secondary objective : complication rate , consequence incidental PET-findings , number hospitalisation sick leave day , volume healthcare consume , experienced health-related quality-of-life ( HRQoL ) , genetic , cytological ( immuno ) histopathological feature nodule . Sample size calculation/data analysis : Based above-mentioned estimate reduction unbeneficial intervention ~73 % ~40 % , least 96 patient nodules &gt; 10 mm need analyze ( 2:1 allocation , α=0.05 , power=0.90 , single-sided Fisher 's exact test ) . After correction nodule size data-attrition , 132 patient need include total . Intention-to-treat analysis perform . Incremental Net Monetary Benefit base total direct cost per patient gain HRQoL-adjusted survival year compute . Cytological , histological genetic parameter FDG-avidity described . Nature extent burden risk associate participation , benefit group relatedness : All patient undergo one FDG-PET/CT scan head/neck ( effective dose : &lt; 3.5 mSv ) ask fill 6 questionnaire 4 timepoints . FDG-PET/CT negative patient experimental arm undergo single confirmatory US ( ±FNAC ) . An interim/posterior analysis control subject perform ensure oncological safety . In case unexpected high false-negative ratio control arm , patient advise undergo surgery .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Nodule</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>1 . Documented history solitary thyroid nodule dominant nodule within multinodular disease , ( USguided ) FNAC perform dedicate radiologist experienced endocrinologist pathologist , demonstrate indeterminate cytological examination ( i.e . Bethesda category III IV ) accord local pathologist confirm central review ; 2 . Scheduled surgical excision ( preferably ) within 2 month inclusion date ; 3 . Age ≥ 18 year ; 4 . Euthyroid state serum thyrotropin ( TSH ) free T4 level within institutional upper low limit normal , measure within 2 month registration . In case suppress TSH : negative 123I , 131I 99mTcO4 scintigraphy must available ( `` cold nodule '' ) ; 5 . In patient multinodular disease dominant nodule , nuclear medicine physician responsible FDGPET/CT scan interpretation must determine whether nodule likely discriminate FDGPET/CT image prior enrolment ; 6 . Willing participate aspect study ; 1 . High priori probability malignancy : FNAC Bethesda category V VI local read central review ; Prior radiation exposure / radiotherapy thyroid ; Prior neck surgery radiation opinion PI disrupt tissue architecture thyroid ; New unexplained hoarseness , change voice , stridor paralysis vocal cord ; In case benign reason find ( e.g . vocal cord edema ) , patient eligible ; Thyroid nodule discover FDGPET positive incidentaloma New cervical lymphadenopathy highly suspicious malignancy ; In case malignancy exclude , patient eligible ; Previous treatment thyroid carcinoma current diagnosis malignancy know metastasize thyroid ; Known metastases thyroid carcinoma ; Known genetic predisposition thyroid carcinoma : Familiar NonMedullary Thyroid Cancer ( NMTC ) Familiar Papillary Thyroid Cancer ( FPTC ) Familiar Adenomatoid Polyposis Coli syndrome ( FAP , Gardner syndrome , APCgene mutations chromosome 5q21 ) Morbus Cowden ( PTEN mutation chromosome 10q23.3 ) PTC / nodular thyroid hyperplasia / papillary renal tumour . Linked locus 1q21 . 2 . Proven benign disease insufficient material cytological diagnosis : FNAC Bethesda category I II local read central review 3 . Performance nonroutine additional diagnostic test alter patient treatment policy ( e.g . mutation analysis cytology ) 4 . Inability undergo randomization : Any patient receive thyroid surgery reason ( e.g . mechanical cosmetic complaint ) . 5 . Inability undergo treatment : Inability undergo surgery opinion surgeon / anaesthetist . 6 . Contraindications FDGPET/CT : Patient evidence infection localize neck 14 day prior FDGPET/CT scan ; Inability tolerate lie supine duration FDGPET/CT examination ( ~1015min ) ; Poorly regulate diabetes mellitus ( see next item ) ; Hyperglycaemia time FDG injection prior PET/CT ( fast serum glucose &gt; 200mg/dL [ &gt; 11.1 mmol/L ] ) ; The use shortacting insulin within 4 hour PET scan allow If female fertile : sign symptom pregnancy positive pregnancy test / breastfeeding ; A formal negative pregnancy test obligatory ( severe ) claustrophobia ; Low dose benzodiazepine allow 7 . General contraindication : Inability give informed consent ; Severe psychiatric disorder ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Thyroid Nodule</keyword>
	<keyword>Indeterminate Cytology</keyword>
	<keyword>FDG-PET/CT</keyword>
	<keyword>Diagnostic Thyroid Surgery</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Cost-Effectiveness</keyword>
	<keyword>Quality-of-Life</keyword>
	<keyword>Thyroidectomy</keyword>
</DOC>